Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. Eastern time on the Investors section of Anebulo's website. The company focuses on solutions for acute cannabinoid intoxication. Its lead candidate, ANEB-001, targets the negative effects of such intoxication and has shown promising results in clinical trials, demonstrating rapid absorption and tolerance.

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors section of Anebulo’s website.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1) with good oral bioavailability and brain penetration (rat brain:plasma ratio of approximately 1.5). Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated, and may lead to weight loss, an effect that is consistent with CB1 antagonism in the central nervous system. For further information about Anebulo, please visit www.anebulo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005302/en/

Anebulo Pharmaceuticals, Inc.

Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063

scott@anebulo.com



Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

Source: Anebulo Pharmaceuticals, Inc.

FAQ

When will Anebulo Pharmaceuticals present at the H.C. Wainwright BioConnect Virtual Conference?

Anebulo Pharmaceuticals will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022.

What time will the Anebulo Pharmaceuticals presentation be available on-demand?

The Anebulo Pharmaceuticals presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. Eastern time.

What is ANEB-001 and what does it aim to treat?

ANEB-001 is Anebulo Pharmaceuticals' lead product candidate designed to reverse the negative effects of acute cannabinoid intoxication.

What are the results of the clinical trials for ANEB-001?

Clinical trials for ANEB-001 have shown it to be rapidly absorbed, well tolerated, and may lead to weight loss.

Where can I find more information about Anebulo Pharmaceuticals?

Further information about Anebulo Pharmaceuticals can be found on their website at www.anebulo.com.